Risk Factors for Acute Upper Gastrointestinal Bleeding

Patient History

• A history of prior upper gastrointestinal bleeding or peptic ulcer disease is the single strongest predictor of recurrent bleeding events. American Heart Association data indicate this factor outweighs all others. 1
• Patients who have previously experienced bleeding complications from peptic ulcer disease are at markedly higher risk for future bleeding. 4

Medication‑Related Risk Factors

Multiple Antithrombotic Agents

• Use of two or more antithrombotic agents (e.g., concurrent anticoagulant + antiplatelet therapy) substantially raises the likelihood of upper GI bleeding. 5

Dual Antiplatelet Therapy

• Dual antiplatelet therapy (aspirin + clopidogrel) increases bleeding risk 2‑ to 3‑fold compared with aspirin alone. 8

Aspirin + Oral Anticoagulant Combination

• Concomitant use of aspirin and an oral anticoagulant further elevates bleeding risk. 6

Single Antiplatelet or NSAID Use With Additional Risk Modifiers

• Aspirin or NSAID use combined with any of the following—age > 60‑65 years, severe medical comorbidity, concurrent corticosteroid therapy, or concurrent anticoagulation—significantly amplifies bleeding risk. 5
• High‑dose NSAID therapy independently increases the risk of upper GI bleeding. 6

Anticoagulant Therapy

• Therapeutic anticoagulation (e.g., warfarin, direct oral anticoagulants) consistently predicts gastrointestinal bleeding. 1
• Overall, anticoagulant use is a reliable predictor of upper GI bleeding across diverse patient populations. 4

Corticosteroid Use

• Oral corticosteroids raise bleeding risk, especially when used together with antiplatelet agents or NSAIDs. 5

Clinical and Demographic Risk Factors

• Advanced age (> 60‑65 years) markedly increases the absolute risk of upper GI bleeding. 1
• Presence of severe medical comorbidity (e.g., advanced heart or renal disease) is associated with higher bleeding incidence. 5

Infectious Risk Factor

• Helicobacter pylori infection is a consistent predictor of upper GI bleeding, particularly in patients with peptic ulcer disease. 1

Cumulative Risk

• The relative risk of gastrointestinal bleeding rises proportionally with the number of adverse risk factors present in an individual patient; multiple concurrent factors (e.g., dual antiplatelet therapy + age > 65 + H. pylori infection) confer substantially higher risk than any single factor alone. 2

Assessment Recommendations

• Clinicians should actively inquire about “hidden” risk factors such as over‑the‑counter aspirin use, which patients often fail to disclose. 5
• The 2022 American Gastroenterological Association (AGA) guidelines stress systematic assessment of all bleeding risk factors before initiating or discontinuing proton‑pump inhibitor (PPI) prophylaxis. 5

Protective Measures

• Proton‑pump inhibitor therapy markedly reduces the likelihood of upper GI bleeding in at‑risk patients. 5